Belantamab Mafodotin |CAS 2050232-20-5|DC Chemicals

Cas No.:	2050232-20-5
pH value:	Corresponds to reference standard: PASS
Non-reduced CE-SDS:	>95%
SEC-HPLC:	>95%
Isoelectric Point:	Corresponds to reference standard
Osmolality:	Corresponds to reference standard: PASS
Peptide mapping:	Corresponds to reference standard: PASS
N-terminal sequence:	Corresponds to reference standard: PASS

Description:	Belantamab mafodotin (GSK2857916) is a humanized, afucosylated, anti-B-cell maturation antigen (BCMA) monoclonal antibody-drug conjugate (ADC) conjugated to MMAF (HY-15579) via a maleimidocaproyl linker (McMMAF, HY-15578). Belantamab mafodotin shows anti-myeloma activity[1][2].
In Vivo:	Belantamab mafodotin signifcantly improves survival compared to vehicle in mice harbouring OPM2 tumours[2]. Animal Model: Mice harbouring OPM2 tumours[2] Dosage: 4 mg/kg Administration: IP, twice weekly for 4 doses Result: Signifcantly improves survival compared to vehicle.
In Vitro:	Belantamab mafodotin binds to human BCMA protein with a Kd of 1 nM[2]. Belantamab mafodotin induces G2/M arrest in multiple myeloma cells in a dose and time dependent manner[2]. Belantamab mafodotin signifcantly promotes phagocytosis of multiple myeloma cells by human macrophages derived from macrophage colony-stimulating factor-stimulated monocytes[2].
References:	[1]. Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221. [2]. Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613.

Cat. No.	Product name	Field of application
A1105	Zanidatamab Zovodotin
A1104	Tusamitamab ravtansine	Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8.
A1103	Vadastuximab talirine
A1102	Anetumab Ravtansine	Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models.
A1101	Mirvetuximab soravtansine	Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage.
A1100	Rovalpituzumab tesirine	Rovalpituzumab tesirine (SC-002) is an antibody-drug conjugate (ADC) with anticancer effects. Rovalpituzumab tesirine contains a DLL3-targeting antibody Rovalpituzumab (HY-P99043) tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. Rovalpituzumab tesirine can be used for the stduy of small cell lung cancer (SCLC).
A1099	Cantuzumab ravtansine	Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts.
A1098	Praluzatamab ravtansine
A1097	Labetuzumab govitecan	Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer.
A1096	Vorsetuzumab mafodotin	Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity.